5 Responses to “Is it time to stop surveying Barrett esophagus?”
M. Brian Fennerty, MD
Editor-in-Chief
NEJM Journal Watch Gastroenterology
Biography | Disclosures | Summaries
Learn more about Gut Check on Gastroenterology.
From NEJM: Recently in Gastroenterology- Ultraprocessed Food on an Ultrafast Track September 18, 2025The Nova food-classification system has advanced efforts to address modern diets of highly processed foods. But it’s unclear whether it can be codified at a national level to support public health.
- Mimicking Complex Receptor Actions with Small(ish) Molecules September 18, 2025As a therapeutic area, type 2 diabetes includes a wide range of treatment options in several mechanistic classes (although metformin has multiple classifications). One of the best therapies, however, is and has always been weight loss through diet and exercise. On the face of it, a weight-loss strategy involving diet...
- An Aspirin a Day for Improved Colorectal Cancer Outcomes September 18, 2025The painkilling, antipyretic, and antiinflammatory properties of aspirin have been known for centuries. The understanding that aspirin targets cyclooxygenase-1 (COX-1) (also known as prostaglandin-endoperoxide synthase 2 [PTGS1]) and COX-2 (also known as PTGS2), which are key enzymes required for prostaglandin synthesis, provided a rationale for using aspirin to treat thrombosis....
- Ultraprocessed Food on an Ultrafast Track September 18, 2025
I’m not a doctor but the thought of money being detrimental to the screening for BE is scary….On the other hand, I’m a business owner and understand how business runs!! Mmmmm…interesting discussion. I’ll keep checking in to see how it unfolds.
I, too, am not a doctor, but I have Barrett esophagus. I’ve been having periodic screenings at my gastroenterologist’s suggestion because my father had esophageal cancer. The incidence of cancer in a population may be low, but it needs to be a decision the doctor and patient make together, depending on the patient’s circumstances and medical history.
I think this issue is exemplary of how different points of view can be conflicting. On one side the societal perspective suggests continuing monitoring of BE isn’t worthwhile, the balance being between effectiveness and cost. On the other side the individual perspective affirms: “a low, or very low risk isn’t no risk at all therefore I’d like to continue monitoring even if it produces little good unless the balance between harm and good is decidely shifted”. The sound rationale against PSA screening conjugates the societal perspective: “it is useless” with the individual perspective: “it can do more harm than good”. Until harm from BE monitoring is documented a clearcut position on this issue will be difficult at a clinical level although I feel there is now adequate evidence to reconsidere BE monitoring in the coverage of Health Plans
We should stop surveying Barrett esophagus，but it is not now，why？TO some patient，it saves money，to others，lt means the lost of the chance of early detection for cancer。so，at least by now，we should continue it，but not to all patient。Who should？maybe
patient with high risks into tumor？Now，who is patient with high risks into tumor？it is the key，if we get the key，we solve the problem。
An asymptomatic person does not need a workup but should be endoscoped if a family history of BE exists. A person with esophagitis symptoms would likely be endoscoped; if dysplastic BE is found, that person needs
followup and possible therapy. If non-dysplastic BE is found, we await the next controlled study to determine the appropriate next step. Simple.